Detection of ALK and KRAS mutations in circulating tumor DNA of patients with advanced ALK-positive NSCLC progressed to crizotinib

In patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC) disease progression occurs after a median of 9-10 months of crizotinib treatment. Several mechanisms of resistance have been identified and include ALK mutations and amplification or the activation of bypassing signaling pathways. Re-biopsy in NSCLC patients represents a critical issue and the analysis of circulating cell-free DNA (cfDNA) has a promising role for the identification of resistance mechanisms.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pY5CvB
via IFTTT